Vaxcyte, Inc.
PCVX
$59.44
-$0.92-1.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.13% | 22.81% | 39.25% | 53.53% | 56.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.33% | 71.22% | 62.18% | 34.35% | 22.86% |
| Operating Income | -64.33% | -71.22% | -62.18% | -34.35% | -22.86% |
| Income Before Tax | -94.39% | -85.73% | -65.25% | -29.46% | -10.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.39% | -85.73% | -65.25% | -29.46% | -10.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.39% | -85.73% | -65.25% | -29.46% | -10.12% |
| EBIT | -64.33% | -71.22% | -62.18% | -34.35% | -22.86% |
| EBITDA | -64.44% | -71.05% | -61.28% | -33.52% | -21.90% |
| EPS Basic | -85.82% | -73.08% | -48.34% | -6.44% | 11.12% |
| Normalized Basic EPS | -85.81% | -73.07% | -48.35% | -6.44% | 11.11% |
| EPS Diluted | -85.82% | -73.08% | -48.34% | -6.44% | 11.12% |
| Normalized Diluted EPS | -85.81% | -73.07% | -48.35% | -6.44% | 11.11% |
| Average Basic Shares Outstanding | 4.90% | 7.10% | 11.58% | 19.32% | 22.50% |
| Average Diluted Shares Outstanding | 4.90% | 7.10% | 11.58% | 19.32% | 22.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |